Microbiotal reverse-engineering: How Finch is moving from fecal microbiota transplant to oral therapy

Microbiotal reverse-engineering: How Finch is moving from fecal microbiota transplant to oral therapy

Finch Therapeutics Inc. is developing an oral alternative to fecal microbial transplant that it believes entails less biology risk than more advanced oral candidates, with more targeted delivery than full microbiome transplants delivered via enema.

Takeda to Develop Finch's Microbiome Therapeutic for IBD

Takeda to Develop Finch's Microbiome Therapeutic for IBD

Takeda is paying Finch Therapeutics $10 million upfront for exclusive, global rights to develop and commercialize the latter’s inflammatory bowel disease (IBD) candidate, FIN-524, together with rights to follow-on products for IBD indications.

Takeda partners with an upstart drugs-from-bugs microbiome player inspired by a fecal transplantation biz

Takeda partners with an upstart drugs-from-bugs microbiome player inspired by a fecal transplantation biz

Back when Mark Smith was working on his PhD at MIT about 6 years ago, his girlfriend’s cousin was infected with C.diff. After 7 reoccurrences following treatment with vancomycin, though, the cousin finally beat it by getting a fecal transplant, with his roommate as the donor.